Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination

BMJ Case Rep. 2021 May 31;14(5):e242220. doi: 10.1136/bcr-2021-242220.

Abstract

Immune thrombocytopenia (ITP) has been widely reported as a complication of SARS-CoV-2 infection, but to our knowledge, there have been no reports on the association of the COVID-19 vaccine with thrombocytopenia. Here, we report a case of secondary ITP in a patient who was recently immunised with the messenger RNA COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).

Keywords: COVID-19; immunological products and vaccines.

Publication types

  • Case Reports

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Purpura, Thrombocytopenic, Idiopathic*
  • SARS-CoV-2
  • Thrombocytopenia*
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine